Welcome to our dedicated page for Starling Oncology news (Ticker: STLN), a resource for investors and traders seeking the latest updates and insights on Starling Oncology stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Starling Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Starling Oncology's position in the market.
Starling Oncology (NASDAQ: STLN) reported second quarter 2026 revenue of $161.3 million, up 34.6% year over year, with gross profit rising 55.2% to $27.2 million. Net loss narrowed to $9.8 million, or $(0.08) per share, and Adjusted EBITDA turned positive at $0.2 million. Cash and cash equivalents reached $41.1 million at June 30, 2026.
According to the company, strong specialty pharmacy performance and growth in capitated lives supported results. Full-year 2026 guidance was raised to revenue of $650–$670 million and gross profit of $105–$110 million, with Adjusted EBITDA now expected at $2–$7 million. Starling also expects about $150 million in 2026 capitated revenue and projects its medical loss ratio at 80%–90% over the next twelve months.